idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
28.07.2021 12:23

Freiburg scientists elucidate immune response after SARS-CoV-2 vaccination

Benjamin Waschow Stabsstelle Unternehmenskommunikation
Universitätsklinikum Freiburg

    T cells prevent severe disease after prime vaccination / Antibodies provide reliable protection against infection only after boost vaccination / Research results published in Nature

    In view of the continuing high numbers of infections, vaccination offers important protection against severe COVID-19 disease. Scientists from the Faculty of Medicine – University of Freiburg have now been able to determine in detail at what time point initial immune protection is established after vaccination with an mRNA-based vaccine and how the reactions of the various components of the human immune system develop over months. The researchers published their results on July 28, 2021 in the online edition of the renowned journal Nature.

    "Already ten days after prime vaccination, there is effective protection against severe disease. At this point, however, neutralizing antibodies preventing the virus from entering cells are barely detectable. Instead, this early protective effect is due to specific T cells controlling the cellular immune response," says Dr. Maike Hofmann, Head of a research group at the Department of Internal Medicine II at Medical Center – University of Freiburg.

    Detailed analysis of the immune response

    The scientists examined blood samples from 32 volunteers before prime vaccination and at intervals of three to four days continuously for up to four months after boost vaccination. This allowed them to follow the development of the different components of the immune response in detail. "In the majority of subjects, a relevant increase in so-called CD8+ T cells precisely tailored to the SARS-CoV-2 spike protein could be detected as early as six to eight days after prime vaccination," reports Prof. Dr. Christoph Neumann-Haefelin, Head of the Gerok Liver Center at Medical Center – University of Freiburg.

    After boost vaccination, the number of CD8+ T cells increased. Only at this point neutralizing antibodies could be detected in quantities large enough to prevent the virus from invading cells and thus the infection itself. "Our results underscore the importance of complete vaccination with two doses of the mRNA vaccine for adequate protection against infection," Neumann-Haefelin adds.

    Highly effective mRNA vaccine technology

    The potent combination of a rapid T-cell response and neutralizing antibodies is evidence of the high efficacy of the still-new mRNA vaccination technology. Follow-up studies will have to show how long protection lasts after boost vaccination and when a second boost vaccination - possibly adapted to new virus variants - will be necessary. "The more precisely we understand how the mRNA vaccination works, the sooner we will be able to develop it further for other diseases - for example, for a future vaccination against hepatitis C or a therapeutic vaccination against cancer," explains Prof. Dr. Robert Thimme, Medical Director of the Department of Internal Medicine II at Medical Center – University of Freiburg.

    "The fact that important insights into the development of a solid immune response to SARS-CoV-2 could be gained and published within a few months is proof of the great expertise and commitment of our researchers," says Prof. Dr. Lutz Hein, Dean of the Faculty of Medicine –University of Freiburg.


    Wissenschaftliche Ansprechpartner:

    Prof. Dr. Robert Thimme, Medical Director
    Prof. Dr. Christoph Neumann-Haefelin, Head of the Gerok Liver Center
    Dr. Maike Hofmann, Head of Research Group
    Department of Medicine II – Gastroenterology, Hepatology, Endocrinology, and Infectious Diesases
    University of Freiburg – Medical Center
    robert.thimme@uniklinik-freiburg.de
    christoph.neumann-haefelin@uniklinik-freiburg.de
    maike.hofmann@uniklinik-freiburg.de


    Originalpublikation:

    Original title of the study: Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
    DOI: 10.1038/s41586-021-03841-4


    Weitere Informationen:

    http://www.nature.com/articles/s41586-021-03841-4


    Bilder

    Merkmale dieser Pressemitteilung:
    Journalisten
    Medizin
    überregional
    Forschungsergebnisse
    Englisch


     

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).